Bravecto

RSS

fluralaner

Authorised
This medicine is authorised for use in the European Union.

Overview

Bravecto is a veterinary medicine used to treat parasitic infestations in dogs and cats. It may be used:

  • to treat flea and tick infestations in dogs and cats
  • as part of the management of flea allergy dermatitis (an allergic reaction to flea bites) in dogs and cats
  • to treat demodectic and sarcoptic mange (skin infestation caused by two different mites) in dogs
  • to treat ear mite infestations in cats.

Bravecto contains the active substance fluralaner.

This EPAR was last updated on 19/11/2019

Authorisation details

Product details
Name
Bravecto
Agency product number
EMEA/V/C/002526
Active substance
fluralaner
International non-proprietary name (INN) or common name
fluralaner
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53BE02
Publication details
Marketing-authorisation holder
Intervet International B.V
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
11/02/2014
Contact address

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

12/09/2019 Bravecto - EMEA/V/C/002526 - II/0036

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • ECTOPARASITICIDES FOR SYSTEMIC USE
  • Isoxazolines

Therapeutic indication

Dogs:

- For the treatment of tick and flea infestations;

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

- For the treatment of demodicosis caused by Demodex canis;

- For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation.

Cats:

- For the treatment of tick and flea infestations;

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

- For the treatment of infestations with ear mites (Otodectes cynotis).

Assessment history

News

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating